Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity
NCT07830329 on ClinicalTrials.gov · last registry update 2026-09-21
An unusually large phase 2: 300 participants, more than double the 110 typical for the stage. Due to report 24 November 2028, alongside 27 other tracked readouts that quarter. Primary outcome, as filed: Percent change in total Abscess and inflammatory Nodule (AN) count. Sponsors move these dates routinely; any movement since this site started watching is listed below. olatorepatide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended. The registry entry has been edited 1 time since then.
- Status
- NOT_YET_RECRUITING
- Phase
- P2
- Drug
- olatorepatide
- Sponsor
- Regeneron Pharmaceuticals
- Sponsor type
- Industry
- Enrollment
- 300
- Started
- 2026-10-30
- Primary completion
- 2028-11-24 estimated
Observed history
Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.
| Detected | Change | Detail |
|---|---|---|
| 2026-09-21 | First seen in registry | Registered as NOT_YET_RECRUITING, P2 |
Primary outcome
Percent change in total Abscess and inflammatory Nodule (AN) count
Conditions studied
Hidradenitis Suppurativa
Every field above is taken directly from the registry record. See all detected changes across the class, or the olatorepatide page for this molecule’s full trial and approval history.